Zabernigg August
Abteilung für Innere Medizin, Bezirkskrankenhaus Kufstein, Kufstein, Osterreich.
Wien Med Wochenschr. 2007;157(21-22):536-9. doi: 10.1007/s10354-007-0480-0.
Non-small cell lung cancer (NSCLC) is the most common malign lung tumour. It is diagnosed in the majority of patients at an advanced stage without a chance for cure despite substantial progress in the therapeutic armamentarium. The therapeutic goals in this situation are prolongation of life and symptom palliation. Both the classical chemotherapy as well as modern therapeutic strategies (tyrosinkinase inhibitors, bevacizumab) are able to achieve these goals. It is currently unclear how to incorporate the new strategies into first line therapy. At the ASCO congress 2007 numerous studies were presented for first line therapy of advanced NSCLC. A large phase III study with bevacizumab and a study with Docetaxel maintenance therapy are to be discussed in detail, followed by a short presentation of a study with platinum-free combinations, a new platinum combination with pemetrexed/carboplatin, the chemotherapy of patients with PS (2/3), and interesting studies with cetuximab.
非小细胞肺癌（NSCLC）是最常见的恶性肺肿瘤。尽管治疗手段有了很大进展，但大多数患者在晚期才被诊断出来，已无治愈机会。这种情况下的治疗目标是延长生命和缓解症状。传统化疗以及现代治疗策略（酪氨酸激酶抑制剂、贝伐单抗）都能够实现这些目标。目前尚不清楚如何将新策略纳入一线治疗。在2007年美国临床肿瘤学会年会上，有许多关于晚期NSCLC一线治疗的研究被公布。将详细讨论一项关于贝伐单抗的大型III期研究以及一项关于多西他赛维持治疗的研究，随后简要介绍一项关于无铂联合方案的研究、一种新的培美曲塞/卡铂铂类联合方案、PS（2/3）患者的化疗，以及关于西妥昔单抗的有趣研究。
